Boston, MA & Hamilton, ON – March 23, 2020 – Fusion Pharmaceuticals Inc., a clinical-stage oncology company focused on developing…
Read More
Boston, MA & Hamilton, ON – March 4, 2020 – Fusion Pharmaceuticals Inc., a clinical-stage oncology company focused on developing…
Boston, MA & Hamilton, ON – February 6, 2020 – Fusion Pharmaceuticals Inc., a clinical-stage precision oncology company developing targeted…
Hamilton, ON & Boston, MA – January 13, 2020 – Fusion Pharmaceuticals Inc., a clinical-stage precision oncology company developing next-generation…
Hamilton, ON & Boston, MA – January 10, 2020 – Fusion Pharmaceuticals Inc., a privately-held, clinical-stage precision oncology company developing…
Background Type I insulin-like growth factor receptor (IGF-1R) is a transmembrane protein which is overexpressed in solid tumors including non–small…
Fusion Pharmaceuticals, a clinical-stage biopharmaceutical company developing targeted alpha-particle radiotherapeutics for treating cancer, announced today that it will present a…
Lead investors Varian and OrbiMed, are joined by Perceptive Advisors, Pivotal bioVenture Partners, Rock Springs Capital and all existing investors…
BOSTON, MA and HAMILTON, ONTARIO, March 4, 2019 – Fusion Pharmaceuticals, a clinical-stage biopharmaceutical company developing targeted alpha-particle radiotherapeutics for treating cancer,…
BOSTON, Massachusetts and HAMILTON, Ontario—February 19, 2019- Fusion Pharmaceuticals, a biopharmaceutical company focused on radiotherapeutics (specifically, targeted alpha therapeutics), today…
